UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________ Securities registered pursuant to Section 12(b) of the Act: FORM 8-K __________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 __________________________ Delaware (State or Other Jurisdiction 455 Grand Union Boulevard, Somerville, MA 02145 (Address of Principal Executive Offices) (Zip Code) blue ...

bluebird bio’s (BLUE) shares have lost 25.4% year to date compared with the industry’s decline of 7.9%.As of now, the going is challenging for bluebird. While the approval of its three gene therapies bodes well, the uptake of the same has not gained traction as expected.Image Source: Zacks Investment ResearchThe FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022. It also approved Skysona for treating early, ...

Who wins this face-to-face between two beaten-down biotechs?If there is one thing Bluebird Bio (BLUE -5.17%) and Novavax (NVAX -0.47%) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop catastrophically in recent years. Bluebird's stock is down by 91% in the past three years, while Novavax's has declined by 97%.The market doesn't have much faith in either company, but if they can turn things around, opportunistic investors who initiate positions n ...

For most stocks, a 25% cut in an analyst's target price following an earnings release would send investors scrambling for the exit door. That wasn't the case with Bluebird Bio (BLUE -6.23%), however.The clinical-stage biotech saw a decent price rise after those two events in late March. What helped was that, despite the cut, said analyst believes the shares are on track to double in price and then some.The price target is cut. However...That prognosticator is Wells Fargo's Yanan Zhu, who now feels Bluebird ...

bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Conference Call March 26, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Conference Call Participants Jason Gerberry - Bank of America Securities Danielle Brill - Raymond James Jack Allen - Baird Gena Wang - Barclays Eric Joseph - JPMorgan Mani Foroohar - Leerink Jeffrey Hung - Morgan Stanley Salveen Richter - Goldman Sachs Sami Corwin - ...

bluebird bio, Inc. (BLUE) announced that it has received a $175 million five-year, term loan facility from Hercules Capital, Inc. (HTGC) . The funding will extend bluebird’s cash runaway by two years. The company’s shares rose 1.4% on the news.Per the terms of the agreement, bluebird will get the term loans in four tranches. The first tranche of $75 million was drawn upon the closing of the transaction. BLUE will be eligible to draw two additional tranches of $25 million each, subject to the achievement of ...

Like many biotechs, Bluebird Bio's (BLUE 1.41%) stock has been volatile over its lifetime. The company, which specializes in gene-editing therapies, has struggled with high costs and limited patient populations for two of its three approved products, plus looming competition for the third. The company was thrown something of a financial lifeline on Monday, however. Cautiously optimistic investors pushed the stock's price up by 1.4% in reaction. That was good enough to beat the S&P 500 index's 0.6% bump high ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The transaction strengthens the Company’s balance sheet as it executes on the commercial launches for its three FDA approved gene therapies – LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy. The term lo ...

Penny stocks -- companies whose shares are trading for $5 or less -- look cheap for a reason: They have encountered severe issues, and the market has little faith that they will turn things around. That's the situation in which Bluebird Bio (BLUE -3.24%), a biotech focused on gene editing, finds itself. The company has made tremendous progress and has proven innovative abilities, but still faces severe headwinds.On the bright side, buying shares today would translate to outsized returns in the long run if t ...

Investors were clearly feeling blue about Bluebird Bio (BLUE -9.15%) on Tuesday. Collectively, they traded the commercial-stage biotech stock down by more than 9% in Tuesday's trading, not long after an analyst cut his price target on the shares. That price decline was far more dramatic than the 1% slip of the S&P 500 index on the day.A deep price cut from HSBCAfter market close on Monday, HSBC's Morten Herholt reduced his Bluebird Bio fair value assessment to $1.02 per share. That represents a 56% cut from ...